Ground‑breaking research at NSW Health Pathology’s anatomical pathology laboratory at Royal North Shore Hospital could transform how cancer is diagnosed and treated, using a simple blood test instead of invasive biopsies.
Congratulations to Professor Anthony Gill and Professor Nick Pavlakis, on securing a $3.75 million Translational Program Grant via Cancer Institute NSW to bring a less invasive method of diagnosing and monitoring cancer into everyday care.
Professor Gill, NSW Health Pathology’s Senior Staff Specialist in Anatomical Pathology at Royal North Shore Hospital, is leading the project with his colleague Professor Pavlakis, oncologist at RNSH and the Kolling Institute.
The research focuses on liquid biopsies, a simple blood test that can detect tiny fragments of DNA released by cancer cells. For some patients, this approach has the potential to replace traditional tissue biopsies and even surgery.
“The great majority of trials of new cancer treatments around the world now include a liquid biopsy component to track the response of the tumours. It is now important to bring capability for this new testing to NSW,” Professor Gill said.
“This new technology can pick up small amounts of DNA shed by cancer in the blood, providing a valuable screening tool and crucial information to guide treatment.
“Liquid biopsies are not only used in the diagnosis of cancer, but to assess whether any cancer has been left behind following surgery, if a cancer has returned and if a tumour is not responding to chemotherapy.
“They will inform treatment approaches after surgery to determine if radiotherapy or chemotherapy are also needed to prevent a cancer returning. We know that if tiny fragments of DNA from the cancer are still in the blood after surgery, then more treatment is needed.
“Liquid biopsies will support personalised care, enabling clinicians to accurately track the effectiveness of targeted treatments, and adjust therapies to meet individual needs.”
Benefits for rural patients
The research could bring significant benefits for patients living in regional and rural areas, who are often required to travel long distances for biopsies.
NSW Health Pathology Chief Executive Vanessa Janissen said supporting cutting-edge research is key to ensuring patients across NSW benefit from emerging technologies.
“Our role is to ensure patients, no matter where they live, have access to advanced diagnostic services that support faster diagnosis, better treatment decisions and improved outcomes,” she said.
“This funding recognises the outstanding expertise within NSW Health Pathology and our partners, and our commitment to remaining at the forefront of innovation in pathology and cancer care.”
Royal North Shore Hospital oncologist and leading University of Sydney researcher Professor Nick Pavlakis has welcomed the multi-million-dollar funding boost, saying liquid biopsies will deliver wide-ranging benefits.
“Liquid biopsies for cancer are not just one test. It is a combination of different tests,” Prof Pavlakis said.
“Some are designed as screening tests, some are designed to predict response to treatment, some are designed to monitor for recurrence. Each different type of test has a different role at different stages of diagnosis and treatment.
“A liquid biopsy tumour bank is being developed so that when patients with cancer have a blood test, they will be given the opportunity to donate a small sample of blood. This will help refine our testing, and progress crucial therapies for a broad range of cancers.”
(Top photo: Prof Nick Pavlakis and Prof Anthony Gill at Royal North Shore Hospital)















